Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion.
OBJECTIVE
Fibroblast growth factor-2 (FGF-2), given during ischemia or during reperfusion of the ischemic heart is cardioprotective, but its mitogenic activity may limit possible clinical applications. We have tested the cardioprotective potential of a non-mitogenic FGF-2 mutant (S117A) that no longer activates casein kinase 2 (CK2) in both acute and long-term studies.


RESULTS
To test effects during reperfusion, the ex vivo rat heart, subjected to 30 min of global ischemia and 60 min of reperfusion was used. S117A FGF-2 administered during reperfusion protected against myocardial contractile dysfunction, activated protein kinase C and decreased the release of cytochrome C in the cytosol. To study effects on ischemic myocytes in the absence of reperfusion, myocardial infarction (MI) was induced in the rat model by irreversible left coronary ligation. S117A-, wild type (wt)-FGF-2 or saline, were administered by intramyocardial injection into the ischemic ventricular wall. One day later, infarct size (assessed by tetrazolium staining), and plasma cardiac troponin T levels (assessed by Western blotting) were significantly decreased in the S117A FGF-2-, compared to the saline-treated group. Systolic pressure, rates of contraction and relaxation and developed pressure, assessed in the Langendorff mode, were significantly improved in the S117-FGF-2 group. Improved ejection fraction and fractional shortening in the S117A-treated group were maintained up to, but not beyond, 7 days post-MI. In comparison, improvements were maintained in the wt-FGF-2-treated group at least up to 6 weeks post-MI. At 6 weeks post-MI, small vessel density (assessed by immunofluorescence-based detection) in the scar bordering viable myocardium was similar between S117A-FGF-2- and saline-treated hearts, but significantly increased in the wt-FGF-2-treated group. This was accompanied by increased coronary flow in the wt-, but not S117A-FGF-2-treated hearts, compared to controls.


CONCLUSIONS
The ability of FGF-2, administered during ischemia or during reperfusion, to protect the myocardium acutely from tissue loss and dysfunction is independent of its potential for CK2 activation and angiogenesis. Non-angiogenic S117A-FGF-2 may be considered in therapies aiming for acute prevention of reperfusion-associated pathologies, especially in cases where use of mitogens is counter-indicated.
Jiang
Zhi-Sheng
ZS
Institute of Cardiovascular Sciences, St. Boniface Research Centre, Department of Human Anatomy and Cell Science and Physiology, University of Manitoba, 351 Tache Avenue, Winnipeg, Manitoba, Canada R2H 2A6.
Srisakuldee
Wattamon
W
Soulet
Fabienne
F
Bouche
Gerard
G
Kardami
Elissavet
E
D000818:Animals; D003326:Coronary Circulation; D045304:Cytochromes c / Q000378:metabolism; D004452:Echocardiography; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000502:physiology*; D008297:Male; D009154:Mutation; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging / Q000378:metabolism*; D015428:Myocardial Reperfusion Injury / Q000000981:diagnostic imaging / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D011493:Protein Kinase C / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D016222:Fibroblast Growth Factor 2; D045304:Cytochromes c; D011493:Protein Kinase C